ANGLE
Point is a financially determined expert clinical symptomatic organization with spearheading items in malignant growth diagnostics and fetal wellbeing. It likewise possesses a fruitful expert innovation consultancy and a significant interest in a business with a one of a kind PC illustrations innovation stage. The business has developed so it currently centers around its laid out 90%+ possessed organizations with one of a kind high-esteem patent-safeguarded clinical innovations tending to extravagant business sectors. Point's lead item is the Parsortix cell partition gadget, which can catch extremely uncommon coursing growth cells (CTCs) in disease patient blood - in any event, when there is short of what one CTC in one billion solid cells. Point has sent off an item for the exploration market and is expecting to get CE Mark administrative endorsement for the clinical market in 2013 with FDA endorsement in 2014. Point has an exceptionally proficient venture model. Costs are limited by the utilization of outsider joint efforts and organizations and by the commitment of its counseling business to overheads. The current organizations are more than six years of age. Point's endeavors are coordinated to amplifying investor gets back from these organizations and there are no designs to set up new organizations. Risk is additionally counterbalanced by the income creating PC illustrations organization, which can possibly convey a close term capital re-visitation of ANGLE. Point was established by Andrew Newland in 1994 to overcome an issue among research and the market. Point's plan of action is to set up, own and work innovation organizations to market a-list research.
Point is a financially determined expert clinical symptomatic organization with spearheading items in malignant growth diagnostics and fetal wellbeing. It likewise possesses a fruitful expert innovation consultancy and a significant interest in a business with a one of a kind PC illustrations innovation stage. The business has developed so it currently centers around its laid out 90%+ possessed organizations with one of a kind high-esteem patent-safeguarded clinical innovations tending to extravagant business sectors. Point's lead item is the Parsortix cell partition gadget, which can catch extremely uncommon coursing growth cells (CTCs) in disease patient blood - in any event, when there is short of what one CTC in one billion solid cells. Point has sent off an item for the exploration market and is expecting to get CE Mark administrative endorsement for the clinical market in 2013 with FDA endorsement in 2014. Point has an exceptionally proficient venture model. Costs are limited by the utilization of outsider joint efforts and organizations and by the commitment of its counseling business to overheads. The current organizations are more than six years of age. Point's endeavors are coordinated to amplifying investor gets back from these organizations and there are no designs to set up new organizations. Risk is additionally counterbalanced by the income creating PC illustrations organization, which can possibly convey a close term capital re-visitation of ANGLE. Point was established by Andrew Newland in 1994 to overcome an issue among research and the market. Point's plan of action is to set up, own and work innovation organizations to market a-list research.
ANGLE has raised $35.7M across 2 rounds. Its most recent round was a Series Unknown of $11.9M in Jun 2024. Full funding history, investors, and team are detailed below.
Funding history
2 rounds on record — latest round shown, the rest unlock with a paid plan.
Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
ANGLE is featured in
Similar companies
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions.
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company's mission is to deliver "instant immunity" through passive immunization, helping protect vulnerable populations such as the elderly, newborns, and immunocompromised patients from severe infectious diseases. The company specializes in the discovery and development of broad-spectrum antiviral antibodies that are engineered to remain effective even as viruses evolve. Its scientific approach combines virology, antibody engineering, computational biology, and immune-directed discovery techniques to identify potent antibodies that target conserved regions of viral proteins, reducing the risk of resistance caused by viral mutations. RQ Bio's lead programs focus on infectious diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). The company is currently developing long-acting monoclonal antibodies designed to provide once-yearly protection against seasonal influenza, particularly for individuals at high risk of severe disease.
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing and novel high value drugs with an unmet commercial or medical need . N4’s commercial strategy is to advance a pipeline of products through clinical proof of concept and then partner to take the products through the relevant regulatory pathway studies to regulatory approval.
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create customizable cell therapies that are compatible with different individuals.
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative materials.
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology. With backing from Invest NI through the EU's Investment for Growth and Jobs Programme, Neurovalens' project will focus on research and development over the coming year to enhance the company's competitiveness.
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps with security and reduces fraud risk.
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Scarlet Therapeutics is developing the novel red blood cell-based therapeutics (tRBCs) generation platform.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.